Days before the Supreme Court ruled that Novartis’ cancer drug Glivec is not a new invention good enough to be granted patent in April.

Until and unless Sun obtains a court decision of non-infringement and/or invalidity on the ’051 patent, it faces the risk of patent infring...

Despite the SC verdict, Indian generics makers won't be falling over each other to take on Big Pharma and launch cheaper versions of their ...

India’s strong stance on minor drug innovations could reverberate in national parliaments and courthouses of the developed world.

A unit of US drugmaker Merck & Co sued India's Glenmark Pharmaceuticals on Tuesday for infringing its patent on two diabetes drugs.

The ruling ends Novartis' attempts to secure a patent for the drug and continues to keep the price of anti-blood cancer drugs low in the co...

IPAB of Chennai has dismissed German pharma major Bayer's plea, seeking a stay on the Compulsory Licence issued to Hyderabad-based drugmake...

Intellectual Property Appellate Board of Chennai dismissed Bayer's plea, seeking a stay on Compulsory License issued to Natco to make Nexav...

The Delhi HC ruling favouring India’s second largest drugmaker Cipla has come as a shot in the arm for other generic makers who are fightin...

The case is considered to have wide implications on public health and local drug industry.

FOR the patent office, the past three years have been like the past three overs of a Twenty20 match.

The Madras High Court ruled that section 3(d) of the Indian Patents Act was constitutional.

Even while somebody bays for his blood, S Chandrasekaran can be calm and imperturbable.

The Indian Patent Appellate Board (IPAB) on Monday heard a case that will decide whether S Chandrasekaran, former controller general of pat...

The groups said India's ability to manufacture low cost generic versions of newer medicines would be threatened if Norvatis won the suit.